

Progressing Our Expansive Pipeline

| ONCOLOGY | | | | Rights | | |
|----------|------------------------------------|--|--------------------------|---|--------|--|
| NGM120 | GFRAL Antagonist Antibody | Cancer & Cancer-related Cachexia | PHASE 1A/1B ¹ | Ph1a/1b Preliminary Data Presented at ESMO 3Q21 | Global | |
| | | Metastatic Pancreatic Cancer & Cancer-related Cachexia | PHASE 2 | Placebo-controlled Expansion Enrolling | Global | |
| NGM707 | ILT2/ILT4 Dual Antagonist Antibody | Advanced Solid Tumors | PHASE 1/2 | Enrolling | Global | |
| NGM831 | ILT3 Antagonist Antibody | Advanced Solid Tumors | IND-ENABLING STUDIES | Ph1 Initiation Expected 1H22 | Global | |
| NGM438 | LAIR1 Antagonist Antibody | Advanced Solid Tumors | IND-ENABLING STUDIES | Ph1 Initiation Expected 1H22 | Global | |

| RETINAL | | | | | |
|---------|-----------------------------|--------------------|---------|----------------------------|---|
| NGM621 | Anti-Complement C3 Antibody | Geographic Atrophy | PHASE 2 | Topline Data Expected 2H22 | Merck option at PoC; if optioned, NGM to receive milestones + double-digit royalties <u>or</u> up to 50% profit/cost share ² |

| LIVER & METABOLIC DISEASES | | | | | |
|----------------------------|-----------------------------|------------|----------|-----------|--|
| MK-3655 (NGM313) | FGFR1c/KLB Agonist Antibody | NASH F2/F3 | PHASE 2B | Enrolling | Merck optioned at PoC; NGM to receive milestones + double-digit royalties <u>or</u> up to 50% profit/cost share ² |
| Aldafermin | FGF19 Analog | NASH F4 | PHASE 2B | Enrolling | Global |

¹ Phase 1a cohort = monotherapy; Phase 1b cohort = in combination with standard-of-care treatment of gemcitabine + Nab-paclitaxel

² At NGM's option at Phase 3

NASH = non-alcoholic steatohepatitis; FGF = fibroblast growth factor; KLB = klotho beta; C3 = Component 3; GFRAL = glial cell-derived neurotrophic factor receptor alpha-like; ILT2 = Immunoglobulin-like transcript 2; ILT4 = Immunoglobulin-like transcript 4; ILT3 = Immunoglobulin-like transcript 3; LAIR1 = Leukocyte-associated immunoglobulin-like receptor 1; stage 2 or 3 or 4 liver fibrosis (F2/F3/F4); PoC = proof of concept